Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such ...

Migraine is linked to a 30% lower risk for dementia and a 42% lower risk for Alzheimer’s disease than not having migraine, a ...

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License ...

By 2030, the population in the United States aged 65 and older is expected to reach 71 million or about 20% of Americans.

A review found obesity and Alzheimer’s disease share metabolic disruptions that may damage brain cells, raising the ...

Lithium chloride may affect many cellular level changes in Alzheimer's disease, a new study from the University of Eastern ...

Cure Alzheimer's Fund, a nonprofit dedicated to funding the most promising research to prevent, slow, or reverse Alzheimer's disease (AD), has announced the recipients of the third annual Jeffrey L.

A new study suggests a surprisingly simple compound could help fight Alzheimer’s disease. Researchers found that arginine—an inexpensive amino acid already considered safe—can reduce the buildup of ...

Detailed price information for Oncotelic Therapeutcs Inc (OTLC) from The Globe and Mail including charting and trades.

The FDA has approved Auvelity for AD agitation. The combination of dextromethorphan and bupropion is the first oral non-antipsychotic approved for this indication.